Cargando…

Breakthrough Bacteremia with Meropenem-resistant Pseudomonas aeruginosa in Hematologic Malignancy Patients Receiving Levofloxacin Prophylaxis

BACKGROUND: Fluoroquinolone (FQ) exposure has been reported to induce Pseudomonas aeruginosa cross-resistance specifically to carbapenems (CP) in vitro but in vivo data are lacking. The purpose of this study was to determine the impact of FQ prophylaxis for high-risk neutropenia on the emergence of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hakki, Morgan, Tallman, Gregory B, Lewis, James S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631045/ http://dx.doi.org/10.1093/ofid/ofx163.1894

Ejemplares similares

2278. Emergence of Resistance and Associated Mortality during Persistent Pseudomonas aeruginosa Bacteremia in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients
por: Fontana, Lauren, et al.
Publicado: (2019)

360. Breakthrough Invasive Pulmonary Aspergillosis During Isavuconazole Prophylaxis in Patients with Hematologic Malignancies: A Single-Center Experience
por: Fontana, Lauren, et al.
Publicado: (2018)

Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital
por: Kimura, Muneyoshi, et al.
Publicado: (2016)

Pseudomonas aeruginosa ExoU-associated virulence in HCT recipients and patients with hematologic malignancies
por: Fontana, Lauren, et al.
Publicado: (2023)

Prophylaxis with levofloxacin: bacterial infections and antimicrobial resistance in hematological malignancies
por: Campos, Claudio Penido
Publicado: (2014)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2019)

1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
por: Ziegler, Matthew, et al.
Publicado: (2018)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

1591. Infectious Outcomes of Levofloxacin Prophylaxis in Obese vs. Non-obese Patients with Hematologic Malignancies
por: Kurtti, Amanda, et al.
Publicado: (2018)

High Rate of Inappropriate Antibiotics in Patients with Hematologic Malignancies and Pseudomonas aeruginosa Bacteremia following International Guideline Recommendations
por: Chumbita, Mariana, et al.
Publicado: (2023)

Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients
por: Zhang, Liyang, et al.
Publicado: (2022)

2685. Oral Third-Generation Cephalosporins vs. Levofloxacin for Antibacterial Prophylaxis in Neutropenic Patients with Hematologic Malignancies
por: DeVoe, Catherine, et al.
Publicado: (2019)

Emergence of meropenem and levofloxacin resistance in Burkholderia pseudomallei in Taiwan
por: Wu, Pin-Han, et al.
Publicado: (2023)

Morphological and Bactericidal Effects of Amikacin, Meropenem and Imipenem on Pseudomonas aeruginosa
por: Moghoofei, Mohsen, et al.
Publicado: (2015)

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa
por: Chachanidze, Vladimir, et al.
Publicado: (2009)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
por: Nussbaumer-Pröll, A., et al.
Publicado: (2022)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
por: Ngo, Hong Loan, et al.
Publicado: (2023)

Emergence of non-susceptibility during persistent Pseudomonas aeruginosa bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients
por: Fontana, Lauren, et al.
Publicado: (2021)

Outbreak of Pseudomonas aeruginosa Bacteremia Infections among Stem-Cell Transplant Patients Related to Change in Prophylaxis
por: VerLee, Kerrie, et al.
Publicado: (2021)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
por: Wang, Yuhang, et al.
Publicado: (2022)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
por: Dahdouh, E., et al.
Publicado: (2014)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
por: Hassuna, Noha Anwar, et al.
Publicado: (2020)

521. Comparative In Vitro Activity of Meropenem/Vaborbactam and Meropenem Against a Collection of Real-World Clinical Isolates of Pseudomonas aeruginosa
por: Patel, Twisha S, et al.
Publicado: (2019)

803. The Impact of Bundled Interventions to Decrease Transmission of Drug-Resistant Pseudomonas aeruginosa from Wastewater Drain Sites on a Hematologic Malignancy/Hematopoietic Stem Cell Transplant Unit
por: Fontana, Lauren, et al.
Publicado: (2021)

Clinical Predictors of Pseudomonas aeruginosa Bacteremia in Emergency Department
por: Choi, Yongsoon, et al.
Publicado: (2018)

Pseudomonas aeruginosa bacteremia among liver transplant recipients
por: Liu, Taohua, et al.
Publicado: (2018)

Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm
por: Alam, Farhana, et al.
Publicado: (2020)

Transcriptional profiling of Pseudomonas aeruginosa mature single- and dual-species biofilms in response to meropenem
por: Alam, Farhana, et al.
Publicado: (2023)

Clinical Impact of Fluoroquinolone-Resistant Escherichia coli in the Fecal Flora of Hematological Patients with Neutropenia and Levofloxacin Prophylaxis
por: Chong, Yong, et al.
Publicado: (2014)

Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae
por: Bang, Ji Hwan, et al.
Publicado: (2013)

Pseudomonas aeruginosa heteroresistance to levofloxacin caused by upregulated expression of essential genes for DNA replication and repair
por: Li, Wen-Ru, et al.
Publicado: (2022)

Effect of combined colistin and meropenem against meropenem resistant Acinetobacter baumannii and Pseudomonas aeruginosa by checkerboard method: A cross sectional analytical study
por: Gunalan, Anitha, et al.
Publicado: (2021)

First Report of bla(OXA-677) with Enhanced Meropenem-Hydrolyzing Ability in Pseudomonas aeruginosa in China
por: Sun, Yue, et al.
Publicado: (2021)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study
por: Babich, Tanya, et al.
Publicado: (2022)

CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
por: Stadtmauer, Edward, et al.
Publicado: (2017)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
por: Chien, Kelly S., et al.
Publicado: (2023)

Treatment of Listeria monocytogenes bacteremia with oral levofloxacin in an immunocompromised patient
por: Ishihara, Yo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ruumk13tm04tft7gmas8d34lv8